Navigation Links
Neuralstem Updates ALS Stem Cell Trial Progress
Date:5/8/2012

technique in up to 18 patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

The first twelve patients were all transplanted in the lumbar (lower back) region of the spine. Of these, the initial six (Cohort A) were all non-ambulatory with permanent paralysis. The first patient was treated on January 20, 2010. Successive surgeries have followed at the rate of one every one-to-two months. The first three patients (Cohort A1) were each treated with five unilateral HSSC injections in L2-L4 lumbar segments, while the next three patients (Cohort A2) received ten bilateral injections (5 on each side) in the same region. The next six patients (Cohort B and C) were all ambulatory. Of these, the first three (Cohort B) received five unilateral injections in the L2-L4 region.  The last three patients (Cohort C) in this study group received ten bilateral injections in the same region.

The trial was then approved to progress to cervical transplantations, with two cohorts of three patients (Cohort D and Cohort E). Cohort D has received five injections in the cervical region of the spinal cord. Cohort E will receive a total of 15 injections, 5 in the cervical region and 10 in the lumbar region.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitt
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Neuralstem Announces Issuance of Core Technology Patent in Europe
2. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
3. Neuralstems ALS Trial on Clinical Hold
4. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
5. Neuralstem Receives FDA Approval to Commence Drug Trial for Major Depression
6. Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
7. Neuralstem Updates ALS Clinical Trial Progress
8. Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial
9. Neuralstem Updates NSI-189 Major Depression Trial
10. Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
11. Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
(Date:7/30/2014)... 30, 2014  Packaging Coordinators, Inc. (PCI) is pleased ... acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is ... the United Kingdom and operates ... and Tokyo , Japan. Penn Pharma ... and Commercial dosage form manufacturing, as well as Clinical ...
(Date:7/30/2014)... LAKE FOREST, Ill., July 30, 2014  Hospira, ... leading provider of injectable drugs and infusion technologies, ... June 30, 2014. Net sales for the quarter ... share were $0.72. (Adjusted* measures exclude specified items ... the attached schedules.) On a U.S. Generally Accepted ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25
... Thirteen Abstracts Will Be Featured at Annual Kidney Care ... leading provider of kidney care services for those diagnosed ... with DaVita Clinical Research(R), today announced that company representatives ... 2009 Spring Clinical Meetings scheduled for March 25-29, 2009 ...
... Pharmaceuticals,Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a ... it has been selected to present the ... to Assess the Safety,Pharmacokinetics (PK) and Pharmacodynamics ... Type 2 Diabetes (T2DM)" at the upcoming ...
Cached Medicine Technology:DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 2DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 3DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 4DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 5Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA) 2
(Date:7/30/2014)... The household income of its residents is the most ... rates of avoidable hospital visits conditions that could be ... settings if treated at an early stage, according to a ... Policy (CSHP). , An analysis of hospital billing records ... in New Jersey found that as an area,s per capita ...
(Date:7/30/2014)... The Hearing Aid Clinics industry is ... 2014. Following a multiyear drop during the recession, the ... expansion of private healthcare coverage and, ultimately, the improving ... Aid Clinics industry revenue will increase at an ... five years to 2014. , According to IBISWorld Industry ...
(Date:7/30/2014)... Francisco, California (PRWEB) July 30, 2014 ... reach USD 5,440.5 million by 2020, growing at an ... to a new study by Grand View Research, Inc. ... prevalence of deafness is expected to serve this market ... usage rates of 100% digital hearing aid technology and ...
(Date:7/30/2014)... genetic mutation linked to obesity respond differently to pictures ... do not have the genetic mutation, according to a ... of Clinical Endocrinology & Metabolism ( JCEM ). ... typically results from a combination of eating too much, ... consumption of appetizing foods that are high in calories ...
(Date:7/30/2014)... died of a caffeine overdose in May highlighted the ... To help prevent serious health problems that can arise ... toward a rapid, at-home test to detect even low ... breast milk. Their report appears in ACS, Journal ... and colleagues note that caffeine,s popularity as a "pick-me-up" ...
Breaking Medicine News(10 mins):Health News:Income is a major driver of avoidable hospitalizations across New Jersey 2Health News:Income is a major driver of avoidable hospitalizations across New Jersey 3Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 2Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 4Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 5Health News:Brain response to appetizing food cues varies among obese people 2
... NASHVILLE, Tenn., Nov. 4 Healthcare Realty,Trust Incorporated ... stock cash,dividend for the quarter ended September 30, ... share, is payable on December 3, 2008 to ... Realty Trust is a real estate investment trust ...
... Covisint to Link Hospitals in Michigan,s "Thumb" ... and Improving Healthcare Delivery, Costs, DETROIT, ... ) today announced that its Covisint subsidiary ... now called,Michigan Thumb Health Information System (THIS). ...
... to reduce acute attacks by lowering serum urate levels, which ... high serum urate levels have been shown to lower the ... the safety and efficacy of febuxostat, a new drug being ... Europe, and a commonly used drug that has been around ...
... team led by Mitchell Lazar, MD, PhD, Director of ... University of Pennsylvania School of Medicine, has used state-of-the-art ... molecular "master regulator" of fat-cell biology is nestled in ... appear online this week in Genes & Development ...
... of animal free and defined cell culture media components will feature ... ... Fort Collins, CO (PRWEB) November 4, 2008 -- InVitria,s ... albumins in cell culture, will be featured at the 2nd International ...
... BeaconEquity.com announces the,availability of Trade Alerts on stocks ... the daily trading notes for free by visiting:, http://www.BeaconEquity.com/m ... (NYSE: WMT ),Advanced Medical Optics Inc. (NYSE: ... (NYSE: EXP ), QLogic Corp. (Nasdaq: QLGC ...
Cached Medicine News:Health News:Healthcare Realty Trust Announces Third Quarter Dividend 2Health News:Compuware Covisint to Securely Connect, Integrate Michigan's Thumb Health Information System 2Health News:Compuware Covisint to Securely Connect, Integrate Michigan's Thumb Health Information System 3Health News:Studies examine treatment for gout and the condition's protective effects 2Health News:Studies examine treatment for gout and the condition's protective effects 3Health News:Penn scientists map molecular regulation of fat-cell genetics 2Health News:InVitria to Present at WilBio's International Cell Engineering Meeting 2Health News:Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: WMT, EYE, ESRX, EXP, QLGC, NSM 2Health News:Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: WMT, EYE, ESRX, EXP, QLGC, NSM 3
Use the Mo Bio Vortex Adapter in conjunction with the Vortex Genie 2 for rapid bead beating procedures. Using the Mo Bio Vortex Adapter is an inexpensive alternative to other bead beating and Fast Pr...
... V-500 with Vacuum Controller V-800 and water-cooled secondary ... Model V-500 is a powerful ... vacuum applications. Applications Ideally suited ... Laboratory vacuum source for instruments including ...
... with Vacuum Controller V-800 Efficiently controls vacuum ... on and off as needed to maintain preset vacuum ... PTFE membrane vacuum pump designed to handle most vacuum ... with up to two rotary evaporators Laboratory ...
... BchiVac V-500 and water-cooled secondary condenser to ... a powerful PTFE membrane vacuum pump designed ... Ideally suited for use with ... Laboratory vacuum source for instruments including vacuum ...
Medicine Products: